SurfaceWise2, a hospital-grade disinfectant that makes surfaces hostile to germs for up to three months, has been launched in Australia by Allied BioServices.
Insufficient manufacturing infrastructure and incorrect handling after dispatch are creating supply shortfalls and wastage around the world.
Preliminary results from the Russian COVID-19 phase 3 vaccine trial suggest that the two-dose vaccine regimen is 91.6% efficacious against symptomatic COVID-19.
Queensland-based company Ellume has announced a US$231.8 million (AU$302.7 million) agreement to accelerate domestic US production of its COVID-19 home tests.
Doctors must now prescribe drugs using their chemical name, not brand names. That's good news for patients.
Novavax has announced that its protein-based COVID-19 vaccine candidate has demonstrated a vaccine efficacy of 89.3% in a Phase 3 clinical trial conducted in the UK.
A patent has been filed for advanced magnetic resonance technology that can detect the pathological signature of COVID-19 without relying on direct detection of the SARS-CoV-2 virus.
Blood cancers are now the second most diagnosed cancers in Australia and the second most common cause of cancer-related deaths, according to the Leukaemia Foundation.
A German study indicates that COVID-19 infection can cause increased sperm cell death, inflammation and oxidative stress, resulting in lower sperm quality and potentially reducing fertility.
A Monash University study reveals that a simple ventilated headboard hood can stop SARS-CoV-2 from spreading between patients and healthcare workers on hospital wards.
With COVID-19 vaccinations set to roll out in less than one month, Australia's hospital pharmacists are preparing for their central role in the administration process.
A modelling study led by UNSW Sydney predicts that global demand for cancer surgery will rise by 52% within two decades, with low-income countries bearing the greatest burden.
A new immunotherapy treatment will be studied in clinical trials, with the aim of preventing dangerous side effects for children who have to undergo stem cell transplants.
The Australian Therapeutic Goods Administration (TGA) has provisionally approved the Pfizer/BioNTech COVID-19 mRNA vaccine, COMIRNATY.
Achieving herd immunity for COVID-19 may be a challenge through current vaccination programs, research from the Imperial College London has found.